Oligonucleotide Therapeutics Society
Recent Articles2026-08-24T06:57:48+00:00
9November, 2022

Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues

In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could change the treatment of genetic diseases. Now, their company’s drug that uses their proprietary technology has been granted orphan drug status by the U.S Food and Drug Administration (FDA). The drug, ABX1100, is designed ...

3November, 2022

Reflections following the 20th annual meeting on oligonucleotide therapeutics

Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman Report, copyright 2022, and reprinted with permission. A Brief History of Oligonucleotide Therapeutics About 50 years ago, several scientists independently conceived of the idea of blocking gene expression with synthetic DNA or RNA “antisense” ...

23September, 2022

Eplontersen May Soon Provide Another Safe, Effective Treatment for People Diagnosed with ATTR

People who have been diagnosed with hereditary transthyretin amyloidosis (ATTRv) may soon have the option of choosing another safe, effective therapy, one that significantly improves quality of life, according to patients who received it in the clinical trial. ATTRv is a progressive, debilitating, fatal disease in which amyloids ...

8September, 2022

The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond

More than 30 years ago, Dr. Stanley Crooke founded Ionis Pharmaceuticals — a biotech company that helped pioneer the now successful technology of antisense oligonucleotides (ASO) despite overwhelming challenges and widespread disbelief. After stepping down last year as the company's CEO, Crooke recently published a perspective of his journey ...

27August, 2022

A Landmark Permanent Treatment for Children Born with a Deadly Immune Disorder

In June 2022, the first stem cell gene therapy of Dutch origin was successfully given to a patient by researchers at the Leiden University Medical Centre (LUMC). A baby with severe congenital immune disorder (SCID) received the complex but one-time treatment, marking the first time stem cell gene therapy ...

16August, 2022

Treating Cardiovascular Disease by Changing a Single Letter of DNA

A simple spelling change in liver DNA could improve the future of cardiovascular disease treatment. On July 12, biotechnology company Verve Therapeutics announced that the first patient had received a novel gene editing medicine designed to permanently reduce "bad" LDL cholesterol — the fatty molecule that causes arteries to ...

Eplontersen May Soon Provide Another Safe, Effective Treatment for People Diagnosed with ATTR

September 23rd, 2022|Categories: Perspectives on Current Science|

People who have been diagnosed with hereditary transthyretin amyloidosis (ATTRv) may soon have the option of choosing another safe, effective therapy, one that significantly improves quality of life, according ...

The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond

September 8th, 2022|Categories: Perspectives on Current Science|

More than 30 years ago, Dr. Stanley Crooke founded Ionis Pharmaceuticals — a biotech company that helped pioneer the now successful technology of antisense oligonucleotides (ASO) despite overwhelming challenges ...

Get the latest news!

  • Category

Go to Top